Literature DB >> 29610753

Insulin degludec U100 is associated with lower risk for severe and symptomatic hypoglycemia as compared with insulin glargine U100 in subjects with type 1 diabetes.

Anastasios Tentolouris1, Ioanna Eleftheriadou1, Nikolaos Tentolouris1.   

Abstract

Entities:  

Year:  2018        PMID： 29610753      PMCID： PMC5879534          DOI： 10.21037/atm.2017.12.28

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  19 in total

1.  Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.

Authors:  T Heise; L Hermanski; L Nosek; A Feldman; S Rasmussen; H Haahr
Journal:  Diabetes Obes Metab       Date:  2012-06-07       Impact factor: 6.577

2.  New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1.

Authors:  Reinhard H A Becker; Raphael Dahmen; Karin Bergmann; Anne Lehmann; Thomas Jax; Tim Heise
Journal:  Diabetes Care       Date:  2014-08-22       Impact factor: 19.112

Review 3.  Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2016-11-21       Impact factor: 19.112

4.  Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

Authors:  Simon Heller; John Buse; Miles Fisher; Satish Garg; Michel Marre; Ludwig Merker; Eric Renard; David Russell-Jones; Areti Philotheou; Ann Marie Ocampo Francisco; Huiling Pei; Bruce Bode
Journal:  Lancet       Date:  2012-04-21       Impact factor: 79.321

Review 5.  How hypoglycaemia can affect the life of a person with diabetes.

Authors:  Brian M Frier
Journal:  Diabetes Metab Res Rev       Date:  2008-02       Impact factor: 4.876

6.  Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.

Authors:  Kåre I Birkeland; Philip D Home; Ulrich Wendisch; Robert E Ratner; Thue Johansen; Lars A Endahl; Karsten Lyby; Johan H Jendle; Anthony P Roberts; J Hans DeVries; Luigi F Meneghini
Journal:  Diabetes Care       Date:  2011-01-26       Impact factor: 19.112

7.  Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.

Authors:  R E Ratner; S C L Gough; C Mathieu; S Del Prato; B Bode; H Mersebach; L Endahl; B Zinman
Journal:  Diabetes Obes Metab       Date:  2012-12-03       Impact factor: 6.577

8.  Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials.

Authors:  Jiten Vora; Torsten Christensen; Azhar Rana; Steve C Bain
Journal:  Diabetes Ther       Date:  2014-08-01       Impact factor: 2.945

9.  Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial.

Authors:  B W Bode; J B Buse; M Fisher; S K Garg; M Marre; L Merker; E Renard; D L Russell-Jones; C T Hansen; A Rana; S R Heller
Journal:  Diabet Med       Date:  2013-06-17       Impact factor: 4.359

Review 10.  A review of the pharmacological properties of insulin degludec and their clinical relevance.

Authors:  Hanne Haahr; Tim Heise
Journal:  Clin Pharmacokinet       Date:  2014-09       Impact factor: 6.447
View more
  3 in total

1.  (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.

Authors:  Bianca Hemmingsen; Maria-Inti Metzendorf; Bernd Richter
Journal:  Cochrane Database Syst Rev       Date:  2021-03-04

2.  Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomized, controlled, open-label, crossover trial.

Authors:  Ulrik Pedersen-Bjergaard; Rikke M Agesen; Julie M B Brøsen; Amra C Alibegovic; Henrik U Andersen; Henning Beck-Nielsen; Peter Gustenhoff; Troels K Hansen; Christoffer Hedetoft; Tonny J Jensen; Claus B Juhl; Andreas K Jensen; Susanne S Lerche; Kirsten Nørgaard; Hans-Henrik Parving; Anne L Sørensen; Lise Tarnow; Birger Thorsteinsson
Journal:  Diabetes Obes Metab       Date:  2021-11-02       Impact factor: 6.408

3.  Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14.

Authors:  Richard E Pratley; Mansoor Husain; Ildiko Lingvay; Thomas R Pieber; Thomas Mark; Hans A Saevereid; Daniel Vega Møller; Bernard Zinman
Journal:  Cardiovasc Diabetol       Date:  2019-11-15       Impact factor: 9.951
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.